Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

Bristol-Myers Squibb Co.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $65.26 USD
Change Today +0.26 / 0.40%
Volume 5.0M
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$65.19
Previous Close
$65.00
Day High
$66.11
Day Low
$65.00
52 Week High
03/20/15 - $69.20
52 Week Low
06/5/14 - $46.30
Market Cap
108.8B
Average Volume 10 Days
6.5M
EPS TTM
$1.38
Shares Outstanding
1.7B
EX-Date
04/1/15
P/E TM
47.4x
Dividend
$1.48
Dividend Yield
2.22%
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company to Approve Amendment to Certificate of Incorporation

Bristol-Myers Squibb Company announced that the annual general meeting to be held on May 5, 2015, to approve amendment to Certificate of Incorporation.

Zai Acquires Exclusive Rights to Oral Brivanib in China from Bristol-Myers Squibb

Zai lab has announced the signature of a licensing agreement with Bristol-Myers Squibb (BMS) whereby Zai lab will obtain exclusive rights in China (including Hong Kong and Macau) to develop, manufacture, and commercialise the anti-VEGFR2 candidate brivanib that is being investigated in Phase III development for oncology indications including hepatocellular carcinoma (HCC). The financial terms of the agreement were not disclosed by the parties.

Bristol-Myers Squibb Company Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3

Bristol-Myers Squibb Company announced that the resubmitted new drug application (NDA) for daclatasvir, an investigational NS5A replication complex inhibitor, has been accepted for review by the U.S. Food and Drug Administration (FDA) for use in combination with sofosbuvir for the treatment of chronic hepatitis C (HCV) genotype 3. The original NDA has been amended to include data from the Phase III ALLY-3 trial, which showed high cure rates for the combination, with sustained virologic response 12 weeks after treatment (SVR12) in 90% of treatment-naïve and 86% of treatment-experienced genotype 3 HCV patients. SVR12 rates were higher (96%) in non-cirrhotic genotype 3 patients, regardless of treatment history. The FDA will now review the submission within a six-month timeframe. Genotype 3 is estimated to affect 54.3 million people worldwide, and is the second most common hepatitis C genotype after genotype 1 (83.4 million). The more aggressive nature of genotype 3 lies in the damage it causes to the liver, as it is associated with progressive disease, increased rates of steatosis and a disproportionately increased risk of hepatocellular carcinoma. In the ALLY-3 study, the daclatasvir and sofosbuvir combination regimen was well tolerated, with no deaths, treatment-related serious adverse events, or discontinuations due to adverse events. The most frequent side effects (=5%) were headache (19.7%), fatigue (19.1%), nausea (11.8%), diarrhea (8.6%), insomnia (5.9%), abdominal pain and arthralgia (both 5.3%). Additionally, there were 17 (11.2%) treatment failures, with 16 relapses post-treatment and 1 rebound at the end of treatment. There were no viral breakthroughs in this ribavirin-free regimen.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $65.26 USD +0.26

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.65 USD +0.38
Biogen Inc $429.87 USD +0.94
Celgene Corp $118.68 USD +1.02
Eli Lilly & Co $73.58 USD +0.14
Novo Nordisk A/S kr369.70 DKK +34.70
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 54.2x
Price/Sales 6.8x
Price/Book 7.3x
Price/Cash Flow 54.1x
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Stock Market News for March 06, 2015 - Market News
  Read More...
BMY battles lung cancer
  Read More...
AbbVie’s Bid Ups Ante as Buyers Bet on Cancer Drugs: Real M&A
  Read More...
AbbVie's Bid Ups Ante as Buyers Bet on Cancer Drugs
  Read More...
Bristol-Myers Squibb
  Read More...
What Analysts Said After Bristol-Myers' Quick Lung Drug Approval
  Read More...